Cloud-Clone launches 13-plex bone metabolism panel

Cloud-Clone unveiled a 13-plex bone-metabolism detection panel built on Luminex technology to quantify 13 biomarkers in a single run from 25 μL samples. The company says the kit is designed to help researchers move beyond single-marker testing for osteoporosis, fracture risk, drug monitoring and other bone disorders.

Why it matters: - Bone-metabolism disorders affect people across the lifespan, from pediatric rickets to osteoporosis, diabetic osteopathy, renal osteodystrophy and rheumatoid-arthritis-related bone erosion. - The new panel is designed to replace fragmented single-marker workflows with broader profiling of bone formation, bone resorption, signaling, inflammation and repair. - Cloud-Clone says the approach can support more precise subtyping, early risk prediction and treatment monitoring in bone-disease research.

What happened: - Cloud-Clone released a 13-plex bone-metabolism detection panel for research use. - The panel uses Luminex liquid-phase microbead technology. - The company says the assay simultaneously measures 13 biomarkers across six research dimensions. - The release dates to Sept. 22, 2026.

The details: - The 13 analytes are ACP5, ALPL, CTXI, DKK1, IL6, LEP, OC, OPG, OPN, PDGF-BB, PINP, RANKL and SOST. - Bone-formation markers include ALPL, PINP and OC. - Bone-resorption markers include ACP5 and CTXI. - Core signaling markers include RANKL, OPG, SOST and DKK1. - IL6 covers inflammatory bone-damage research. - LEP supports studies of fat-bone crosstalk. - OPN and PDGF-BB support research on bone repair, fracture healing, micro-injury and bone fibrosis. - Cloud-Clone says 25 μL of sample is enough for all 13 measurements. - The company says matched antibody pairs provide a 1,000- to 10,000-fold dynamic range versus equivalent ELISA formats and 10- to 100-fold higher sensitivity. - Cloud-Clone says the panel is compatible with Luminex systems and flow cytometers. - The panel is intended for studies of osteoporosis, diabetic osteopathy, renal osteodystrophy, rheumatoid-arthritis-induced bone erosion, hypophosphatemic bone disorders and fracture repair. - Cloud-Clone says the assay can help with mechanistic studies, clinical subtyping, drug-effect monitoring, fracture-risk prediction and drug-target discovery.

Between the lines: - The launch reflects a broader shift in bone research away from bone-mineral-density-only assessment and toward multi-analyte pathway analysis. - The company is positioning multiplex testing as a way to make better use of limited clinical specimens and to connect skeletal biology with immune, metabolic and inflammatory pathways. - Cloud-Clone is leaning on its broader assay library and long-standing multiplex platform to signal technical maturity and reproducibility.

What's next: - Cloud-Clone says it will continue developing multiplex detection technologies and supporting global bone-metabolism research. - Wider adoption of panoramic panels could push research workflows toward earlier warning, finer disease subtyping and more personalized intervention strategies.